Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-090-1 | CAS number: 103-23-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Summary
The data show that DEHA, administered orally to mice, rats, and monkeys, is readily absorbed, distributed to various tissues, metabolized and excreted in urine and to a lesser extent in feces and as exhaled CO2 (CMA, 1984 study report). Dose-dependent changes in absorption, tissue uptake, metabolism, and elimination could be found. Sex differences were apparent in the hepatic uptake and metabolism. The data indicate little, if any, prolonged retention of DEHA or its metabolites in blood and tissue after oral administration in all three species. As could be expected based on the high logPoW of app. 9, dermal penetration is fairly limited.
Hydrolysis and Absorption in Mice
14C-DEHA and/or its metabolites was rapidly absorbed from the GI tract. The highest 14C levels were found in blood and liver 1 or 3 hr after dosing. In the GI tracts large amounts of the diester (DEHA) , monoester (MEHA) and alcohol (EH) were found. The quantities of DEHA decreased with time while other products increased. The major metabolites in the livers were more polar than EH. In general, only small amounts of DEHA, MEHA and EH were found. The livers of male mice also contained large amounts of an early eluting metabolite which was found in female livers in only small quantities. The extent of the two major metabolites recovered in livers of female mice differed significantly.
Dermal absoption
After occlusive application of 5 or 100 mg DEHA as a component of a roll-on deodorant onto human breast skin in vitro, 50 to 20% did not penetrate the skin, while 20 - 30% stayed within the skin. No differentiation was made in the study between stratum corneum and further layers of the skin. Only a small fraction (< 0.1%) were absorped through the skin at a constant rate of 2.2ng/cm²/h within 24h. Because DEHA is highly lipophilic, low penetration and high retention within and on top of the skin meet the expectations. But limited solubility of DEHA in the receiver solution (app. factor 4 above the actual concentration reached during the experiment) might lead to an underestimation of the maximum penetration, despite the use of a non-static system. Additionally, only 56 - 81% of the initial amount of DEHA was recovered. One explantion might be hydrolysis by esterases in the skin, which could lead to an additional uptake of DEHA metabolites.
Disposition in Mice
Preliminary studies with males: after treatment with 50 and 500 mg/kg 14C-DEHA, 95-102% of the 14C was eliminated in urine, feces and expired air within 24 hr. After 5,000 mg/kg, most of the 14C was excreted in 24 hr but ~12% were also recovered in the GI tracts. Definitive studies with male and female mice (50, 500 and 5,000 mg/kg 14C-DEHA): urinary elimination of 14C was rapid and extensive. About 91% of the low and mid doses were eliminated in urine in 24 hr; only 75% after 5,000 mg/kg. Elimination in feces was 7-8% at the low and mid doses and 4% at the high dose. The latter group showed high recovery in the GI tract. Only 0.8 to 1.2% in males and 1.5 to 3.8% in females were eliminated in the expired air. Respiratory elimination was highest in the female low dose group. Only small amounts were found in blood and tissue 24 and 48 hr after dosing. Adrenals and livers showed the highest levels at low and mid dose, especially in males. After 5,000 mg/kg, blood also contained high 14C levels; blood and liver content of the females were significantly higher than of males. At 48 hr, the skin (both sexes) and the fat (females) showed higher retention of 14C than other tissues.
Disposition in Rats and Monkeys
Compared to mice, rats showed lower elimination in urine(~74%) and higher in feces(~20%). 14C elimination in the expired air was 1.4 to 2.1%. About 4% of the dose was recovered in the GI tract. 14C levels in livers and adrenals were higher than in other tissues. Males showed significantly higher tissue contents than the females. Tissue contents in rats were higher than in mice treated with 500 mg/kg (same conditions). The monkeys also showed rapid elimination of 14C in urine and to a lesser extent in feces. Absorption was rapid, as indicated by the fast rates of elimination and by the fast appearance of 14C in blood after 2 hr. Radioactivity disappeared faster from blood of male monkeys compared to females. At 48 hr following dosing, the skin, fat, and livers of males showed the highest levels. In females the 14C concentrations in livers were significantly higher than in other tissues.
Metabolism
The data show that DEHA is rapidly hydrolyzed to the monoester, then the alcohol and acid, without accumulation of MEHA. Supporting data from an in vitro study indicate that this reaction already takes place in the small intestine after oral exposure (in vitro half life of DEHA = 6min) (Eastman, 1984). The alcohol is oxidized by ß-oxidation, W-, and W-l oxidation generating acids, ketones, keto-acids, hydroxy acids, and diacids. Metabolism appeared to be less extensive in monkeys, which mostly excreted MEHA and EH (as their glucuronides). In contrast, mice and rats mostly excreted products of faster oxidation, mainly glucoronidated EHA, 5-OH EHA and diEHA.
In humans and monkeys EHA (glucuronide) plays only a minor role (CMA, 1984).
In an in vitro study with human liver microsomes, 1-mono-(2 -ethyl-5-hydroxyhexyl) adipate (5OH-MEHA) and 1-mono-(2-ethyl-5 -oxohexyl) adipate (5oxo-MEHA) were additionally identified as metabolites, but only at 1/10 to 1/1000 of the concentration of adipic acid (Manori, 2013). In studies with human volunteers similar metabolites were found in urine. However, 1-mono-(2-ethyl-5 -carboxylpentyl) adipate (5cx-MEPA) was excreted at considerably higher concentrations compared to 5oxo-MEHA and 5OH-MEHA (Nehrig, 2019) and MEHA was only a minor metabolite of low quantitative relevance compared to the oxidized monoester metabolites (Nehrig, 2020).
In another study 5OH-MEHA was detected at a significantly lower frequency in finger nails than in urine in humans, suggesting that its accumulation is rather low (Alves, 2017).
MEHA was also found in fecal samples (Loftus, 1993, IUCLID chapter 7.10.5).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
